

Probiotic–Pathogen Interactions in the Human Microbiome: Mechanisms of Antagonism and Therapeutic Potential Against Infectious Diseases

Dr. Khushbu Gautam

PHD Microbiology

Abstract

The human microbiome contains trillions of microorganisms that interact dynamically with host physiology and immune systems. Among these microbes, probiotic bacteria play a crucial role in maintaining microbial balance and protecting the host from pathogenic organisms. Probiotics are defined as live microorganisms that confer health benefits when administered in adequate amounts. Increasing evidence suggests that probiotics interact directly and indirectly with pathogenic microbes through mechanisms including bacteriocin production, competitive exclusion, immune modulation, and biofilm disruption. These interactions contribute to the prevention and management of infectious diseases, particularly those involving gastrointestinal, respiratory, and urogenital pathogens.

Recent studies highlight that probiotic strains such as *Lactobacillus*, *Bifidobacterium*, and *Bacillus* species can inhibit pathogen colonization by producing antimicrobial metabolites and occupying ecological niches that pathogens would otherwise exploit. Probiotics also stimulate host immune responses by interacting with intestinal epithelial cells and immune receptors, thereby enhancing innate and adaptive immunity. Furthermore, probiotic metabolites including short-chain fatty acids, hydrogen peroxide, and bacteriocins play a critical role in suppressing pathogen growth and virulence.

This review provides a comprehensive analysis of the interactions between probiotics and pathogenic microorganisms, emphasizing molecular mechanisms, antimicrobial activity, immune modulation, and clinical implications. Understanding these interactions may facilitate the development of novel probiotic-based therapies to combat antimicrobial-resistant pathogens and improve host health.

Keywords: probiotics, pathogenic bacteria, microbiome, bacteriocins, immune modulation, microbial competition.

1. Introduction

The human body hosts complex microbial communities collectively known as the microbiota. These microorganisms play essential roles in metabolism, immune regulation, and protection against pathogens. The gastrointestinal tract alone contains more than 10^{14} microbial cells belonging to diverse bacterial phyla such as Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria. The balance between beneficial microbes and pathogenic organisms is critical for maintaining host health.

Disruption of this microbial equilibrium, a condition known as dysbiosis, can increase susceptibility to infectious diseases and inflammatory disorders. In recent years, probiotics have gained attention as potential therapeutic agents capable of restoring microbial balance and preventing pathogen colonization. Probiotic microorganisms interact with pathogens through multiple mechanisms, including direct antimicrobial activity and indirect modulation of host immunity. Studies have shown that probiotic bacteria can inhibit pathogenic species by producing antimicrobial compounds, competing for adhesion sites and nutrients, and enhancing host immune responses.

These interactions create a hostile environment for pathogens and contribute to the prevention of infections. The growing prevalence of antibiotic-resistant pathogens has further increased interest in probiotic-based strategies as alternative or complementary approaches to antimicrobial therapy.

2. Diversity of Probiotic Microorganisms

Probiotics consist of various bacterial species that exert beneficial effects on host health.

Common probiotic genera

- *Lactobacillus*
- *Bifidobacterium*
- *Bacillus*
- *Enterococcus*
- *Saccharomyces* (yeast probiotic)

These organisms are frequently present in fermented foods such as yogurt, kefir, and fermented vegetables. Many probiotic strains colonize the gastrointestinal tract and interact with host epithelial cells. Through these interactions, probiotics influence host immunity, metabolic functions, and pathogen resistance.

3. Pathogenic Microorganisms Targeted by Probiotics

Probiotics demonstrate antagonistic activity against several pathogenic bacteria.

Major pathogens inhibited by probiotics

- *Escherichia coli*
- *Salmonella enterica*
- *Clostridioides difficile*
- *Listeria monocytogenes*
- *Staphylococcus aureus*

These pathogens are responsible for severe gastrointestinal and systemic infections.

Table 1. Major Probiotic Bacteria and Their Target Pathogens

Probiotic species	Target pathogen	Mechanism
<i>Lactobacillus rhamnosus</i>	<i>E. coli</i>	Competitive adhesion
<i>Lactobacillus plantarum</i>	<i>Listeria</i>	Bacteriocin production
<i>Bifidobacterium longum</i>	<i>Salmonella</i>	Immune modulation
<i>Bacillus subtilis</i>	<i>Clostridium difficile</i>	Antimicrobial metabolites

4. Mechanisms of Probiotic–Pathogen Interaction


4.1 Production of Bacteriocins

Bacteriocins are antimicrobial peptides produced by probiotic bacteria that inhibit the growth of competing microorganisms.

Bacteriocins disrupt the cell membrane of pathogenic bacteria, causing leakage of cellular contents and eventual cell death. These molecules exhibit potent antimicrobial activity against several pathogens including *Listeria*, *Salmonella*, and *Staphylococcus*.

Additionally, some bacteriocins interfere with pathogen metabolic pathways and DNA synthesis.

4.2 Competitive Exclusion of Pathogens



Competitive exclusion refers to the ability of probiotics to occupy ecological niches and prevent pathogen colonization.

Probiotics adhere to epithelial cells and consume nutrients required for pathogen growth. As a result, pathogenic bacteria are unable to establish themselves in the intestinal environment.

Research indicates that probiotic strains such as *Lactobacillus rhamnosus* compete with pathogens like *E. coli* and *Salmonella* for adhesion sites on intestinal epithelial cells.

4.3 Immune System Modulation

Probiotics interact with host immune cells to regulate immune responses.

These microorganisms stimulate immune receptors such as:

- Toll-like receptors (TLRs)
- NOD-like receptors
- Pattern recognition receptors

Activation of these receptors triggers signaling pathways that promote the production of cytokines and antimicrobial peptides.

Probiotics also enhance the activity of macrophages, dendritic cells, and T lymphocytes, strengthening the host's defense against pathogens.

Table 2. Mechanisms of Probiotic Antagonism Against Pathogens

Mechanism	Description
Bacteriocin production	Antimicrobial peptides destroy pathogens
Organic acid production	Lowers pH inhibiting bacterial growth
Competitive exclusion	Prevents pathogen colonization
Immune modulation	Stimulates host immune response
Biofilm disruption	Prevents pathogen persistence

5. Role of Probiotics in Preventing Infectious Diseases

Probiotics have been investigated for the prevention and treatment of several infections.

Gastrointestinal infections

Probiotics reduce the severity of diarrhea caused by pathogens such as *Salmonella* and *E. coli*.

Respiratory infections

Some probiotic strains enhance immune responses in respiratory mucosa.

Urogenital infections

Probiotics help restore microbial balance in the vaginal microbiota.

Studies show that probiotics can significantly reduce pathogen colonization and infection severity by strengthening host immunity and interfering with pathogen virulence mechanisms.

6. Probiotics and Antimicrobial Resistance

Antimicrobial resistance is a major global health problem. Excessive antibiotic use has contributed to the emergence of multidrug-resistant pathogens.

Probiotics represent a promising alternative because they inhibit pathogens through natural ecological mechanisms rather than conventional antibiotics.

These microorganisms can suppress pathogen virulence, reduce infection risk, and restore microbial balance without promoting resistance.

7. Clinical Applications of Probiotics

Several clinical studies have evaluated probiotic therapies for infectious diseases.

Examples include:

- treatment of antibiotic-associated diarrhea
- prevention of *Clostridioides difficile* infection
- reduction of respiratory tract infections

Probiotic supplementation has also been explored in immunocompromised patients and individuals undergoing antibiotic therapy.

8. Future Perspectives

Although probiotics show promising therapeutic potential, several challenges remain.

Future research should focus on:

- identifying strain-specific probiotic effects
- developing targeted probiotic therapies
- understanding host–microbiome interactions

Advances in microbiome sequencing and systems biology will facilitate the discovery of new probiotic strains with enhanced antimicrobial properties.

Advanced Tables for Probiotic–Pathogen Interaction Study

Table 1. Major Probiotic Genera and Their Biological Characteristics

Probiotic genus	Gram reaction	Common sources	Key biological properties	Clinical significance
<i>Lactobacillus</i>	Gram-positive	Fermented dairy products, human gut	Lactic acid production, bacteriocins	Gastrointestinal health, pathogen inhibition
<i>Bifidobacterium</i>	Gram-positive	Human intestine, fermented foods	SCFA production, immune modulation	Prevention of diarrhea, gut microbiota balance
<i>Bacillus</i>	Gram-positive	Soil, fermented foods	Spore formation, antimicrobial metabolites	Stability in supplements, pathogen suppression
<i>Enterococcus</i> (probiotic strains)	Gram-positive	Gut microbiota	Bacteriocin production	Competitive inhibition of pathogens
<i>Saccharomyces boulardii</i>	Yeast	Probiotic supplements	Anti-toxin activity, immune modulation	Treatment of antibiotic-associated diarrhea

Table 2. Major Pathogenic Microorganisms Targeted by Probiotics

Pathogen	Type	Disease caused	Probiotic antagonism mechanism
<i>Escherichia coli</i>	Gram-negative	Gastroenteritis	Competitive adhesion, organic acids
<i>Salmonella enterica</i>	Gram-negative	Foodborne infection	Bacteriocin production
<i>Listeria monocytogenes</i>	Gram-positive	Listeriosis	Antimicrobial peptides
<i>Clostridioides difficile</i>	Gram-positive	Antibiotic-associated diarrhea	Microbiota restoration
<i>Staphylococcus aureus</i>	Gram-positive	Skin infections, sepsis	Bacteriocins and immune activation

Table 3. Mechanisms of Probiotic Antagonism Against Pathogens

Mechanism	Description	Example probiotic strain
Bacteriocin production	Antimicrobial peptides that disrupt pathogen cell membranes	<i>Lactobacillus plantarum</i>
Organic acid production	Lactic acid and acetic acid reduce pH and inhibit pathogens	<i>Bifidobacterium longum</i>

Mechanism	Description	Example probiotic strain
Competitive exclusion	Probiotics occupy adhesion sites preventing pathogen colonization	<i>Lactobacillus rhamnosus</i>
Biofilm disruption	Probiotics inhibit pathogen biofilm formation	<i>Bacillus subtilis</i>
Immune modulation	Activation of immune cells and cytokine production	<i>Lactobacillus casei</i>

Table 4. Clinical Applications of Probiotics in Infectious Disease Control

Clinical condition	Pathogen involved	Probiotic strain used	Therapeutic outcome
Antibiotic-associated diarrhea	<i>Clostridioides difficile</i>	<i>Saccharomyces boulardii</i>	Reduced infection recurrence
Gastroenteritis	<i>E. coli</i>	<i>Lactobacillus rhamnosus</i>	Shortened disease duration
Respiratory infection	Multiple pathogens	<i>Lactobacillus casei</i>	Improved immune response
Vaginal infection	<i>Candida albicans</i>	<i>Lactobacillus acidophilus</i>	Restored microbial balance

Table 5. Probiotic Metabolites With Antimicrobial Activity

Metabolite	Produced by	Mode of action	Target pathogens
Lactic acid	<i>Lactobacillus</i>	Lowers pH inhibiting pathogen growth	<i>Salmonella, E. coli</i>
Bacteriocins	<i>Lactobacillus, Enterococcus</i>	Membrane disruption	<i>Listeria, Staphylococcus</i>
Hydrogen peroxide	<i>Lactobacillus</i>	Oxidative damage to pathogens	Vaginal pathogens
Short-chain fatty acids	<i>Bifidobacterium</i>	Inhibits pathogen metabolism	Intestinal pathogens

9. Conclusion

Probiotic microorganisms play a crucial role in maintaining microbial balance and protecting the host from pathogenic infections. Through mechanisms such as bacteriocin production, competitive exclusion, and immune modulation, probiotics effectively inhibit pathogenic microbes and enhance host immunity. The growing understanding of probiotic–pathogen interactions has opened new avenues for the development of probiotic-based therapeutic strategies. Continued research in this field will contribute to improved management of infectious diseases and reduction of antimicrobial resistance.

References

- Mazziotta, C., et al. (2023). Probiotics mechanism of action on immune cells. *Cells*. <https://doi.org/10.3390/cells12010184>
- Liu, Y., et al. (2022). Modulation of gut microbiota and immune system by probiotics. *Frontiers in Nutrition*. <https://doi.org/10.3389/fnut.2021.634897>

3. Vinayamohan, P., et al. (2024). Efficacy of probiotics in reducing pathogenic potential. *Fermentation*. <https://doi.org/10.3390/fermentation10120599>
4. Umair, M., et al. (2022). Probiotic-based bacteriocin. *Frontiers in Microbiology*. <https://doi.org/10.3389/fmicb.2022.876058>
5. Raheem, A., et al. (2021). Modulatory effects of probiotics during pathogenic infections. *Frontiers in Immunology*. <https://doi.org/10.3389/fimmu.2021.616713>
6. Zhu, J., et al. (2023). Mechanisms of probiotic Bacillus against infections. *One Health Advances*. <https://doi.org/10.1186/s44280-023-00020-0>
7. Zeng, J., et al. (2025). Microbiota and immune interactions. *MedComm*. <https://doi.org/10.1002/mco2.70265> □ Mazziotta C, et al. Probiotics and immune system interactions. *Cells*. 2023;12:184. doi:10.3390/cells12010184.
8. Liu Y, et al. Gut microbiota modulation by probiotics. *Front Nutr*. 2022;8:634897. doi:10.3389/fnut.2021.634897.
9. Vinayamohan P, et al. Probiotic antimicrobial mechanisms. *Fermentation*. 2024;10:599. doi:10.3390/fermentation10120599.
10. Umair M, et al. Probiotic bacteriocins against pathogens. *Front Microbiol*. 2022;13:876058. doi:10.3389/fmicb.2022.876058.
11. Raheem A, et al. Immune modulation by probiotics. *Front Immunol*. 2021;12:616713. doi:10.3389/fimmu.2021.616713.
12. Zhu J, et al. Bacillus probiotics against infections. *One Health Adv*. 2023;1:20. doi:10.1186/s44280-023-00020-0.
13. Zeng J, et al. Microbiota and immunity interactions. *MedComm*. 2025;6:e70265. doi:10.1002/mco2.70265.
14. Sanders ME, et al. Probiotics and human health. *Gastroenterology*. 2020;159:697-705. doi:10.1053/j.gastro.2020.05.059.
15. Hill C, et al. Expert consensus on probiotics. *Nat Rev Gastroenterol Hepatol*. 2021;18:719-730. doi:10.1038/s41575-021-00464-5.
16. O'Toole PW, et al. Microbiome and probiotics. *Nat Rev Microbiol*. 2021;19:715-731. doi:10.1038/s41579-021-00535-1.
17. Derrien M, et al. Probiotics in microbiome health. *Nat Rev Gastroenterol Hepatol*. 2022;19:459-472. doi:10.1038/s41575-022-00582-6.
18. Zhang L, et al. Probiotic mechanisms in pathogen inhibition. *Front Cell Infect Microbiol*. 2021;11:772637.
19. Plaza-Díaz J, et al. Mechanisms of probiotic action. *Nutrients*. 2020;12:356.
20. Vieira AT, et al. Gut microbiota and immunity. *Nat Rev Immunol*. 2020;20:155-170.
21. Bron PA, et al. Probiotic–host interactions. *Nat Rev Microbiol*. 2021;19:361-372.
22. Peterson CT, et al. Immune modulation by probiotics. *Clin Microbiol Rev*. 2022;35:e00167-21.
23. Li X, et al. Probiotic antimicrobial metabolites. *Front Microbiol*. 2021;12:668.
24. Yang B, et al. Probiotic competition with pathogens. *Microorganisms*. 2023;11:211.
25. Liu Z, et al. Probiotic bacteriocin activity. *Appl Microbiol Biotechnol*. 2022;106:1125-1140.
26. Zheng J, et al. Genomics of Lactobacillus species. *Nat Microbiol*. 2020;5:278-287.